KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Goodwill: 2009-2024

Historic Goodwill for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $107.5 million.

  • Novavax's Goodwill fell 10.80% to $113.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.1 million, marking a year-over-year decrease of 10.80%. This contributed to the annual value of $107.5 million for FY2024, which is 15.67% down from last year.
  • Per Novavax's latest filing, its Goodwill stood at $107.5 million for FY2024, which was down 15.67% from $127.5 million recorded in FY2023.
  • Over the past 5 years, Novavax's Goodwill peaked at $135.4 million during FY2020, and registered a low of $107.5 million during FY2024.
  • In the last 3 years, Novavax's Goodwill had a median value of $126.3 million in 2022 and averaged $120.4 million.
  • Its Goodwill has fluctuated over the past 5 years, first surged by 164.65% in 2020, then decreased by 15.67% in 2024.
  • Novavax's Goodwill (Yearly) stood at $135.4 million in 2020, then decreased by 2.88% to $131.5 million in 2021, then dropped by 3.92% to $126.3 million in 2022, then rose by 0.89% to $127.5 million in 2023, then declined by 15.67% to $107.5 million in 2024.